Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Oxford Nanopore Technologies Cash Conversion Cycle Related Terms
Oxford Nanopore Technologies Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OXFYY vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Oxford Nanopore Technologies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oxford Nanopore Technologies Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oxford Nanopore Technologies's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Oxford Nanopore Technologies's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Oxford Nanopore Technologies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oxford Nanopore Technologies (OXFYY) has a Cash Conversion Cycle of 204.16 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oxford Nanopore Technologies and its competitors.
Is Oxford Nanopore Technologies' Cash Conversion Cycle too high?
Oxford Nanopore Technologies' current Cash Conversion Cycle is 204.16. The Biotechnology industry median Cash Conversion Cycle is 102.45. Oxford Nanopore Technologies' value of 204.16 is 99.3% above this industry median. Overall, Oxford Nanopore Technologies has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Oxford Nanopore Technologies' Cash Conversion Cycle compare to VRTX and REGN?
Oxford Nanopore Technologies' Cash Conversion Cycle of 204.16 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 102.45. Oxford Nanopore Technologies' value of 204.16 is 99.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 102.45, based on 873 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oxford Nanopore Technologies's current Cash Conversion Cycle of 204.16 is 99.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Oxford Nanopore Technologies and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 102.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oxford Nanopore Technologies's current Cash Conversion Cycle is 204.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford Nanopore Technologies stock overvalued right now?
Based on GuruFocus' analysis, Oxford Nanopore Technologies (OXFYY) is currently considered Significantly Undervalued. The stock's GF Value™ is $9.79, compared to a current price of $6.50 — trading 33.6% below its estimated fair value. The current Cash Conversion Cycle is 204.16 and 99.3% above the Biotechnology industry median of 102.45. Oxford Nanopore Technologies' overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Oxford Nanopore Technologies (OXFYY), the current Cash Conversion Cycle is 204.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oxford Nanopore Technologies (OXFYY) Overvalued in 2026?
Based on GuruFocus' analysis, Oxford Nanopore Technologies stock appears to be undervalued.
The current stock price of $6.50 is trading 33.6% below its estimated GF Value™ of $9.79.
GuruFocus considers Oxford Nanopore Technologies to be Significantly Undervalued.
Key valuation signals for OXFYY:
Cash Conversion Cycle: 204.16
GF Value™: $9.79 vs. price of $6.50 (33.6% below fair value)
Industry Position: 99.3% above the Biotechnology median
No single metric tells the full story. See the OXFYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oxford Nanopore Technologies PLC is involved in researching, developing, manufacturing and commercializing deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that provides rich data, is fast, accessible and easy to use, and which allows the real-time analysis of DNA or RNA. It has developed and brought to market a new generation molecular sensing platform based on nanopores. The first application is DNA/RNA sequencing and the platform is also being developed for the analysis of proteins and metabolites. It operates in single segment of providing products and services related to the sale and use of its nanopore-based sensing technology. Geographically its operations are spread across EMES, AMR, and APAC.
50GF Score
Get the complete analysis for OXFYY
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OXFYY has been successfully added to your 
